Bristol Myers Squibb (CELG-RI) Change in Receivables (2009 - 2026)

Bristol Myers Squibb has disclosed Change in Receivables across 18 years of filings, most recently posting -$1.7 billion for Q1 2026.

• In Q1 2026, Change in Receivables fell 11146.67% year-over-year to -$1.7 billion; the TTM figure through Mar 2026 stood at -$1.4 billion (down 788.5% YoY), while the FY2025 annual figure was $295.0 million, up 211.74% from the prior year.
• Change in Receivables declined to -$1.7 billion in Q1 2026, from -$19.0 million in the prior quarter.
• Over the last five years, Change in Receivables for CELG-RI reached as high as $1.0 billion in Q2 2024 and fell as low as -$1.7 billion in Q1 2026.
• The 5-year median for Change in Receivables is $65.0 million (2023), against an average of $117647.1.
• Annual changes were most pronounced in 2024 — Change in Receivables soared 1467.69% — and 2026, when it plunged 11146.67%.
• A 5-year view of Change in Receivables shows it stood at $106.0 million in 2022, then jumped by 379.25% to $508.0 million in 2023, then tumbled by 128.15% to -$143.0 million in 2024, then surged by 86.71% to -$19.0 million in 2025, then tumbled by 8778.95% to -$1.7 billion in 2026.
• According to Business Quant data, Change in Receivables over the past three periods registered -$1.7 billion, -$19.0 million, and -$155.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.